Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
PRME is expected to report earnings to rise 34.38% to -43 cents per share on February 27
Q4'25
Est.
$-0.43
Q3'25
Beat
by $0.11
Q2'25
Beat
by $0.02
Q1'25
Beat
by $0.04
Q4'24
Beat
by $0.18
The last earnings report on November 07 showed earnings per share of -31 cents, beating the estimate of -43 cents. With 2.16M shares outstanding, the current market capitalization sits at 689.55M.
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. PRME showed earnings on November 07, 2025. You can read more about the earnings report here.